Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KT-A832
- Development stage
- Preclinical
- Lead developer
- Kriya Therapeutics
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intrapancreatic
01
Overview
**KT-A832** is an investigational AAV-based gene therapy developed by Kriya Therapeutics for type 1 diabetes. Administered via intrapancreatic injection, it delivers a gene encoding modified insulin-like growth factor 1 (IGF-1) to enable local production of this protein in the pancreas, aiming to restore insulin sensitivity and beta cell function in a durable, one-time treatment. The program leverages Kriya's platform for prevalent diseases, with preclinical status as of available data.[1][4][6]
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)IGF-1 (Insulin-like growth factor 1)
Beyond the preview
Go deeper on KT-A832.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KT-A832.